Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 7,800 shares of Atara Biotherapeutics stock in a transaction dated Tuesday, August 7th. The shares were sold at an average price of $37.43, for a total transaction of $291,954.00. Following the sale, the chief executive officer now owns 812,613 shares in the company, valued at $30,416,104.59. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
NASDAQ:ATRA traded up $0.50 on Friday, reaching $40.95. The stock had a trading volume of 373,800 shares, compared to its average volume of 731,218. The firm has a market cap of $1.81 billion, a PE ratio of -10.21 and a beta of 2.55. Atara Biotherapeutics Inc has a 1-year low of $12.65 and a 1-year high of $54.45.
Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported ($1.15) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.98) by ($0.17). analysts expect that Atara Biotherapeutics Inc will post -4.58 earnings per share for the current fiscal year.
ATRA has been the topic of several recent research reports. Jefferies Financial Group reiterated a “buy” rating and set a $45.00 target price on shares of Atara Biotherapeutics in a research report on Friday, August 3rd. Canaccord Genuity restated a “buy” rating and issued a $70.00 price target on shares of Atara Biotherapeutics in a research report on Tuesday, May 8th. BidaskClub lowered shares of Atara Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 8th. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, June 6th. Finally, Citigroup reduced their price target on shares of Atara Biotherapeutics from $25.00 to $23.00 and set a “sell” rating on the stock in a research report on Monday, June 11th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $43.17.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Featured Story: Average Daily Trade Volume – ADTV
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.